Impact of atrial fibrillation on outcomes of aortic valve implantation

Raheel Ahmed, Department of Cardiology, Northumbria Healthcare National Health Service Foundation Trust, Newcastle, United Kingdom.
Hiroyuki Sawatari, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota; Department of Perioperative and Critical Care Management, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Saurabh Deshpande, Jayadeva Institute of Cardiac Sciences and Research, Bangalore, India.
Hassan Khan, Division of Cardiology, Emory University, Atlanta, Georgia.
Providencia Rui, Department of Cardiology, Barts Heart Centre, Barts Health National Health Service Trust, London, United Kingdom; Department of Cardiology, Newham University Hospital, Barts Health National Health Service Trust, London, United Kingdom.
Mohammed Y. Khanji, Department of Cardiology, Barts Heart Centre, Barts Health National Health Service Trust, London, United Kingdom; Department of Cardiology, Newham University Hospital, Barts Health National Health Service Trust, London, United Kingdom; National Institute for Health Research Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Akil A. Sherif, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota; Department of Medicine, Saint Vincent Hospital, Worcester, Massachusetts.
Keerthi Jaliparthy, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Sathish Reddy, Jayadeva Institute of Cardiac Sciences and Research, Bangalore, India.
Vuyisile T. Nkomo, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Cholenahally N. Manjunath, Jayadeva Institute of Cardiac Sciences and Research, Bangalore, India.
Cha Yong-Mei, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Virend K. Somers, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Peter A. Brady, Advocate Aurora HealthFollow
Anwar A. Chahal, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota; Department of Cardiology, Barts Heart Centre, Barts Health National Health Service Trust, London, United Kingdom; Cardiac Electrophysiology Section, Division of Cardiovascular Diseases, University of Pennsylvania, Philadelphia, Pennsylvania.
Deepak Padmanabhan, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota; Jayadeva Institute of Cardiac Sciences and Research, Bangalore, India. Electronic address: deepak.padmanabhan@gmail.com.

Affiliations

Advocate Heart Institute

Abstract

New or preexisting atrial fibrillation (AF) is frequent in patients undergoing aortic valve replacement. We evaluated whether the presence of AF during transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) impacts the length of stay, healthcare adjusted costs, and inpatient mortality. The median length of stay in the patients with AF increased by 33.3% as compared with those without AF undergoing TAVI and SAVR (5 [3 to 8] days vs 3 [2 to 6] days, p < 0.0001 and 8 [6 to 12] days vs 6 [5 to 10] days, p < 0.0001, respectively). AF increased the median value of adjusted healthcare associated costs of both TAVI ($46,754 [36,613 to 59,442] vs $49,960 [38,932 to 64,201], p < 0.0001) and SAVR ($40,948 [31,762 to 55,854] vs $45,683 [35,154 to 63,026], p < 0.0001). The presence of AF did not independently increase the in-hospital mortality. In conclusion, in patients undergoing SAVR or TAVI, AF significantly increased the length of stay and adjusted healthcare adjusted costs but did not independently increase the in-hospital mortality.

Document Type

Article

PubMed ID

34772477

Teammate Access

Link to Full Text

 

Share

COinS